Aethlon Medical, Inc. (AEMD) EPS Estimated At $-0.16; Anworth Mortgage Asset Has 1.34 Sentiment

October 17, 2017 - By reb123z

Anworth Mortgage Asset Corporation is a real estate investment trust . The company has market cap of $591.16 million. The Company’s investment objective is to provide risk-adjusted total returns to its stockholders over the long-term primarily through dividends and secondarily through capital appreciation. It has a 10.02 P/E ratio. The Company’s strategy is to invest in residential mortgage-backed securities (MBS) (both Agency MBS and Non-Agency MBS), residential mortgage loans and residential rental properties.

Analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report $-0.16 EPS on November, 9.They anticipate $0.13 EPS change or 44.83% from last quarter’s $-0.29 EPS. After having $-0.21 EPS previously, Aethlon Medical, Inc.’s analysts see -23.81% EPS growth. About 78,544 shares traded. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 56.57% since October 17, 2016 and is downtrending. It has underperformed by 73.27% the S&P500.

Doheny Asset Management Ca holds 0.98% of its portfolio in Anworth Mortgage Asset Corporation for 347,600 shares. American Financial Group Inc owns 1.42 million shares or 0.81% of their US portfolio. Moreover, Global X Management Co Llc has 0.32% invested in the company for 1.70 million shares. The Texas-based Afam Capital Inc. has invested 0.27% in the stock. Century Capital Management Llc, a Massachusetts-based fund reported 241,211 shares.

About 16,996 shares traded. Anworth Mortgage Asset Corporation (ANH) has risen 26.52% since October 17, 2016 and is uptrending. It has outperformed by 9.82% the S&P500.

Aethlon Medical, Inc. is a medical device firm focused on creating devices for cancer, infectious disease and other life-threatening conditions. The company has market cap of $14.70 million. The Firm operates through two divisions: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. It currently has negative earnings. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 reb123z




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: